Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study
- Conditions
- Localized Osteosarcoma
- Registration Number
- NCT03737435
- Lead Sponsor
- Istituto Ortopedico Rizzoli
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria:<br><br> 1. Patients with primary localized osteosarcoma who received chemotherapy +/-<br> mifamurtide according to ISG-OS2/GEIS-33 trials,<br><br> 2. Paraffin-embedded tissue tumor (FFPE) blocks from archive available to perform the<br> biological analysis<br><br> 3. Written informed consent prior to any study-specific analysis and/or data collection<br><br>Exclusion Criteria:<br><br> 1) Patients with diagnosis different from osteosarcoma<br><br>
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterize the immunephenotype in patients with localized osteosarcoma treated with chemotherapy +/- mifamurtide for primary osteosarcoma;Correlate the rate of immune cells, and the level of the PDL-1 checkpoint with event-free survival and overall-survival
- Secondary Outcome Measures
Name Time Method